摘要
Abstract
Objective To investigate the clinical efficacy of Cisplatin in treating patients with non-small cell lung cancer, and the rela-tionship between adverse reactions and pharmacokinetics. Methods Totally 42 patients with non-small cell lung cancer admitted to our hospital from September 2015 to September 2016 were treated with intravenous drip of 20 mg/m2·d of Cisplatin for 3 days, 3 weeks for 1 courses, and the patients received continuous treatment for 4 courses. Serum samples were collected dynamically, the pharmacokinet-ic characteristics of Cisplatin were detected, and the adverse reactions and clinical efficacy were observed during the course of treat-ment. Results After treating by Cisplatin, the total effective rate was 40. 47% ( 17/42 ) in 42 patients with non-small cell lung can-cer. The AUC of the control group was higher than that of the progressive group, but t1/2β was lower than that of the progression group ( P < 0. 05 ) , but there was no significant difference of Cmax, CL and t1 /2α in the two groups ( P > 0. 05 ) . The Cmax in the nephrotoxic group and the leukopenia group were significantly higher than those in the non-hepatotoxicity group and the non-leukopenia group ( P < 0. 05 ) , and the t1/2α of leukopenia group was significantly lower than that of non-leukopenia group ( P < 0. 05 ) . Conclusion The AUC of Cisplatin can be used as an adjunct to the evaluation of clinical curative effect in the treatment of non-small cell lung can-cer, and Cmax is associated with nephrotoxicity and leukopenia.关键词
顺铂/非小细胞肺癌/药代动力学/临床疗效/药品不良反应Key words
Cisplatin/non-small cell lung cancer/pharmacokinetics/clinical efficacy/adverse drug reaction分类
医药卫生
